PARABILIS MEDICINES INC
PBLSNASDAQ🏆 #1517 by market capUS Equity
$29.52—
Last available close · quote unavailableTrack PBLS
Get earnings, price moves & breaking news on Telegram
24h—
7d▲ 9.8%
14d▲ 17.2%
30d▼ 7.4%
ytd—
1y—
🏦Market Cap
$3.48B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- —
- 52-Week Range
- $22.66 – $42.49
- Volume (shares)
- —
- Avg Volume (shares)
- —
- Shares Outstanding
- 122.0M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- $148,000
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-2.04
- Dividend Yield
- —
PARABILIS MEDICINES INC
PBLSFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$152M▲ +20.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$124M▲ +18.7% YoY
StockOtter · stockotter.spaceAbout PARABILIS MEDICINES INC
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
⚡Momentum★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.
Latest News & Updates
News unavailable.